Cargando…
Gene Therapy for Liver Cancers: Current Status from Basic to Clinics
The liver is a key organ for metabolism, protein synthesis, detoxification, and endocrine function, and among liver diseases, including hepatitis, cirrhosis, malignant tumors, and congenital disease, liver cancer is one of the leading causes of cancer-related deaths worldwide. Conventional therapeut...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966544/ https://www.ncbi.nlm.nih.gov/pubmed/31769427 http://dx.doi.org/10.3390/cancers11121865 |
_version_ | 1783488760190599168 |
---|---|
author | Kamimura, Kenya Yokoo, Takeshi Abe, Hiroyuki Terai, Shuji |
author_facet | Kamimura, Kenya Yokoo, Takeshi Abe, Hiroyuki Terai, Shuji |
author_sort | Kamimura, Kenya |
collection | PubMed |
description | The liver is a key organ for metabolism, protein synthesis, detoxification, and endocrine function, and among liver diseases, including hepatitis, cirrhosis, malignant tumors, and congenital disease, liver cancer is one of the leading causes of cancer-related deaths worldwide. Conventional therapeutic options such as embolization and chemotherapy are not effective against advanced-stage liver cancer; therefore, continuous efforts focus on the development of novel therapeutic options, including molecular targeted agents and gene therapy. In this review, we will summarize the progress toward the development of gene therapies for liver cancer, with an emphasis on recent clinical trials and preclinical studies. |
format | Online Article Text |
id | pubmed-6966544 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69665442020-01-27 Gene Therapy for Liver Cancers: Current Status from Basic to Clinics Kamimura, Kenya Yokoo, Takeshi Abe, Hiroyuki Terai, Shuji Cancers (Basel) Review The liver is a key organ for metabolism, protein synthesis, detoxification, and endocrine function, and among liver diseases, including hepatitis, cirrhosis, malignant tumors, and congenital disease, liver cancer is one of the leading causes of cancer-related deaths worldwide. Conventional therapeutic options such as embolization and chemotherapy are not effective against advanced-stage liver cancer; therefore, continuous efforts focus on the development of novel therapeutic options, including molecular targeted agents and gene therapy. In this review, we will summarize the progress toward the development of gene therapies for liver cancer, with an emphasis on recent clinical trials and preclinical studies. MDPI 2019-11-25 /pmc/articles/PMC6966544/ /pubmed/31769427 http://dx.doi.org/10.3390/cancers11121865 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Kamimura, Kenya Yokoo, Takeshi Abe, Hiroyuki Terai, Shuji Gene Therapy for Liver Cancers: Current Status from Basic to Clinics |
title | Gene Therapy for Liver Cancers: Current Status from Basic to Clinics |
title_full | Gene Therapy for Liver Cancers: Current Status from Basic to Clinics |
title_fullStr | Gene Therapy for Liver Cancers: Current Status from Basic to Clinics |
title_full_unstemmed | Gene Therapy for Liver Cancers: Current Status from Basic to Clinics |
title_short | Gene Therapy for Liver Cancers: Current Status from Basic to Clinics |
title_sort | gene therapy for liver cancers: current status from basic to clinics |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966544/ https://www.ncbi.nlm.nih.gov/pubmed/31769427 http://dx.doi.org/10.3390/cancers11121865 |
work_keys_str_mv | AT kamimurakenya genetherapyforlivercancerscurrentstatusfrombasictoclinics AT yokootakeshi genetherapyforlivercancerscurrentstatusfrombasictoclinics AT abehiroyuki genetherapyforlivercancerscurrentstatusfrombasictoclinics AT teraishuji genetherapyforlivercancerscurrentstatusfrombasictoclinics |